Adriamycin is part of a class of drugs callend anthracylcines (Adriamycin/doxirubicin & Ellence/ebirubicin are two common anthracylines used to treat breast cancer). While these drugs are considered quite effective, they carry with them a risk of cardiotoxicity that increases with each subsequent dose.
Cumulative risk of chronic heart failure Source: http://annonc.oxfordjournals.org/content/early/2009/01/19/annonc.mdn728.full |
As of this December, I have received 425 mg/m2 of adriamycin (including the 4 doses I had in 2005 + the weekly adriamycin I have been receiving since September). Even though the adriamycin seems to be working, we are at the point where the risks of further treatment will likely outweight the benefits. Given that I am still feeling relatively healthy and there are a number of other chemotherapy regimens out there still to try, we will be shelving the adriamycin and moving on to another drug (TBD).
There may come a day when the benefits do outweigh the risks of adriamycin (if we do not find another drug that controls my tumor burden)... so we may see the red devil again someday... but for now, I thank her for the work that she has done for me and I look forward to the next stage of this battle.
No comments:
Post a Comment